Streetbeat News

Products Services

CSTL

Castle Biosciences has published two studies supporting the clinical need for its MyPath Melanoma gene expression profile test, which aids in diagnosing ambiguous melanocytic lesions.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2024 | 11:12 am

APLS

Apellis Pharmaceuticals announced an oral presentation on the Phase 3 VALIANT study of Pegcetacoplan in C3G and primary IC-MPGN at the American Society of Nephrology Kidney Week.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2024 | 11:11 am

EYEN

Eyenovia will present successful Phase 3 study results of Clobetasol Propionate Suspension 0.05% (APP13007) for treating inflammation and pain post-ocular surgery at the American Academy of Ophthalmology 2024 Expo.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2024 | 11:09 am

GSK

PFE

ViiV Healthcare, owned by GSK, Pfizer, and Shionogi, presented new data on Apretude, a long-acting HIV pre-exposure prophylaxis. The data highlights its effectiveness, adherence, and quality-of-life improvements.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2024 | 11:08 am

RIO

Rio Tinto (NYSE:RIO) reported weaker-than-expected Q3 production, missing analysts' estimates. Despite short-term challenges, the company is optimistic about organic growth, with new projects in lithium and iron ore. The $6.7 billion acquisition of Arcadium Lithium is seen as a strategic move, despite a 90% premium. Rio Tinto's shares are slightly down in premarket trading.

Portfolio Pulse from Stjepan Kalinic

October 16, 2024 | 11:08 am

CYN

Cyngn has announced a new patent for its autonomous vehicle solutions, which could enhance its technological capabilities and market position.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2024 | 11:07 am

BLRX

BioLineRx has announced that the United States Patent and Trademark Office (USPTO) has allowed a new composition of matter patent for Motixafortide. This patent strengthens BioLineRx's intellectual property portfolio and could enhance its competitive position in the market.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2024 | 11:07 am

ACB

Aurora Cannabis has launched a new range of medical cannabis oil products in Australia, offering various cannabinoid ratios to cater to diverse patient needs. These products are now available for physicians to prescribe.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2024 | 11:06 am

CATX

LNTH

Perspective Therapeutics has announced the first shipment and patient dosing from its new manufacturing facility in Somerset, New Jersey, for its radiopharmaceuticals. This facility, previously operated by Lantheus Holdings, will support clinical studies and meet future demands.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2024 | 11:06 am

OKYO

OKYO Pharma has commenced patient screening and recruitment for a Phase 2 trial of OK-101 for neuropathic corneal pain. The trial will involve 48 patients and aims to measure pain relief using the Visual Analog Scale.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2024 | 11:05 am